fixed infobox links Tag: Visual edit |
m →History: Task 16: replaced (0×) / removed (1×) deprecated |dead-url= and |deadurl= with |url-status=; Tag: AWB |
||
Line 18: | Line 18: | ||
In May 2016, the company announced it would launch partnership with [[Celgene]],<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/celgene-agios-launch-1b-metabolic-immuno-oncology-alliance/81252736/|title=Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN|work=GEN}}</ref> developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.<ref>{{cite web|first1=Sean|last1=Williams|date=3 June 2016|title=3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016|url=https://www.fool.com/investing/2016/07/03/3-big-reasons-agios-pharmaceuticals-inc-has-plunge.aspx|publisher=The Moteley Fool|access-date=13 July 2018}}</ref> |
In May 2016, the company announced it would launch partnership with [[Celgene]],<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/celgene-agios-launch-1b-metabolic-immuno-oncology-alliance/81252736/|title=Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN|work=GEN}}</ref> developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.<ref>{{cite web|first1=Sean|last1=Williams|date=3 June 2016|title=3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016|url=https://www.fool.com/investing/2016/07/03/3-big-reasons-agios-pharmaceuticals-inc-has-plunge.aspx|publisher=The Moteley Fool|access-date=13 July 2018}}</ref> |
||
In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.<ref name=":0">{{Cite news|url=http://www.bizjournals.com/boston/news/2017/04/19/agios-bags-250m-in-offering-as-cancer-drug-speeds.html|title=Agios bags $250M in offering as cancer drug speeds toward approval |
In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.<ref name=":0">{{Cite news|url=http://www.bizjournals.com/boston/news/2017/04/19/agios-bags-250m-in-offering-as-cancer-drug-speeds.html|title=Agios bags $250M in offering as cancer drug speeds toward approval|date=April 19, 2017|work=Boston Business Journal}}</ref> |
||
In December 2017, the company filed a new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for [[Ivosidenib]] for the treatment of adult patients with relapsed or refractory acute myeloid |
In December 2017, the company filed a new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for [[Ivosidenib]] for the treatment of adult patients with relapsed or refractory acute myeloid |
Revision as of 01:20, 28 September 2019
Company type | Public |
---|---|
Nasdaq: AGIO Russell 1000 Component | |
Industry | Pharmaceuticals |
Founded | 2008 |
Headquarters | , United States |
Key people | Jackie Fouse (CEO) |
Website | agios |
Footnotes / references Foundation[1] |
Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway.[1][2] Among the proteins under investigation by the company are IDH1 and IDH2.[3] The company was founded in 2008 (or 2007)[3] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[1][4] The company tendered an initial public offering in July 2013.[5]: Table 1
History
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.[3]
In May 2016, the company announced it would launch partnership with Celgene,[6] developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.[7]
In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.[8]
In December 2017, the company filed a new drug application, or NDA, with the U.S. Food and Drug Administration, or FDA, for Ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, or R/R AML with an IDH1 mutation.[9]
Corporate governance
As of April 2017, Agios' CEO was David Schenkein.[8]
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.[3][5]
References
- ^ a b c Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. (ed.). The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
{{cite book}}
: External link in
(help); Unknown parameter|chapterurl=
|chapterurl=
ignored (|chapter-url=
suggested) (help); Unknown parameter|editorlink=
ignored (|editor-link=
suggested) (help) - ^ Anton, Ted (2013). "Chapter 13". The Longevity Seekers (Google eBook). University of Chicago Press. p. 163. ISBN 9780226020938.
{{cite book}}
: External link in
(help); Unknown parameter|chapterurl=
|chapterurl=
ignored (|chapter-url=
suggested) (help) - ^ a b c d Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times.
{{cite news}}
: Unknown parameter|deadurl=
ignored (|url-status=
suggested) (help) - ^ "AGIOS PHARMACEUTICALS, INC". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
- ^ a b Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. Vol. 31, no. 12. pp. 1068–71.
- ^ "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN.
- ^ Williams, Sean (3 June 2016). "3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016". The Moteley Fool. Retrieved 13 July 2018.
- ^ a b "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.
- ^ Agios Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2017.